Value-based procurement (VBP) is a journey, not a sprint. It’s about putting the patient at the centre of quality affordable healthcare through changes in procurement practices for medical technologies. Patient outcomes drive value and sustainability, not just price. The bigger picture indicates that VBP will create system cost saving through benefitting patients, rather than trying to attain the reverse – a win-win outcome.
Transforming from our price-based sourcing model to a value-based approach requires the sharing of goals and collaborative effort from all stakeholders – doctors, patients, procurement professionals, MedTech professions.
In this AHJ interview William Downey, Customer Solutions Partner ANZ, Johnson & Johnson Medical talks about working with Dr John Rooney, Head of Orthopaedics, St Vincents Hospital, Sydney and Sarah Sweeney, Operational Transformation & Service Innovation Manager, St Vincents Hospital Network, Sydney, on how St Vincents Hospital Network, implemented Value Based Procurement by working with a MedTech supplier and for the ultimately benefit to the patient.
-
State of private healthcare in Australia
Australia’s healthcare system is often described as a mixed system, with a combination of public and private providers. While public healthcare through Medicare provides universal coverage for essential services, private healthcare offers additional options and amenities for those who can afford them.
Private Healthcare Australia (PHA) is the Australian private health insurance industry’s peak representative body that currently has 21registered health funds throughout Australia and collectively represents 98% of people covered by private health insurance. PHA member funds today provide healthcare benefits for over 14 million Australians.
-
Research funded to investigate early-onset bowel cancer progression
Bowel Cancer Australia recently announced a team led by Professor Michael Samuel as the successful applicant for a three-year $600k early-onset bowel cancer research project through the 2023 round of Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
